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Construction of small molecule ligand (SML) based delivery systems has been performed starting from 
a polyfunctionalized isoxazoline scaffold, whose αvβ3 and α5β1 integrins’ potency has been already 
established. The synthesis of this novel class of ligands was obtained by conjugation of linkers to 
the heterocyclic core via Huisgen-click reaction, with the aim to use them as “shuttles” for selective 
delivery of diagnostic agents to cancer cells, exploring the effects of the side chains in the interaction 
with the target. Compounds 17b and 24 showed excellent potency towards α5β1 integrin acting as 
selective antagonist and agonist respectively. Further investigations confirmed their effects on target 
receptor through the analysis of fibronectin-induced ERK1/2 phosphorylation. In addition, confocal 
microscopy analysis allowed us to follow the fate of EGFP conjugated α5β1 integrin and 17b FITC-
conjugated (compound 31) inside the cells. Moreover, the stability in water solution at different values 
of pH and in bovine serum confirmed the possible exploitation of these peptidomimetic molecules for 
pharmaceutical application.
In the last decades, a major challenge in cancer chemotherapy has been the discovery of a “magic bullet” to kill 
tumors without affecting the healthy tissues, through highly selective treatments1,2. It is well known that standard 
chemotherapies are strongly limited by high toxicities against normal tissues, leading to severe side-effects for the 
patients. Unfortunately, reduction of the administered doses often results in failure of the therapy. Identification 
of molecular and physiological differences between healthy and cancerous tissues has recently allowed the design 
of agents capable to selectively deliver cytotoxic molecules to cancer cells, thereby reducing the off-target effects 
of traditional chemotherapy3.
These composite systems can be divided into three components: a targeting unit, a linker bond and a toxic 
agent4. The targeting ligand should be capable of selective binding to tumor-overexpressed antigens in order to 
recognize cancer cells. Among the number of different receptors and proteins involved in tumor physiology, αvβ3 
and α5β1 integrins are highly expressed on activated endothelial cells in several tumors, playing predominant 
roles in tumor-induced angiogenesis and growth5. For this reason, peptides and peptidomimetics designed to 
mimic the recognition sequence RGD (Arg-Gly-Asp)6, present in the extracellular endogenous ligands of these 
receptors, have received great attention as targeting motives7. Their exploitation as therapeutic tools, per se, is 
still an option but some recent unsatisfactory results8 prompted the researchers to turn their attention towards 
the possible use of these ligands as shuttles for selective delivery of therapeutic payloads and diagnostics9. To this 
purpose, the molecules should possess the proper pharmacophore for effective ligand-receptor interaction but 
also a peripheral and chemically functionalizable anchorage for covalent ligation of diverse spacers and bioactive 
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units. The final backbone and conformation, anyway, should mirror the one of the lead candidates to guarantee 
the bioactivity. To date, drug-targeting has been successfully realized by the conjugation of potent anticancer 
drugs with monoclonal antibodies (mAb)10,11, furnishing compounds that are currently on the market. On the 
other hand, small molecules–drug conjugates (SMDCs) have been proposed as a possible alternative since they 
may be cheaper than biologics and display a better pharmacokinetic profile12.
The design of the second component, i.e. the linker, should take into account the fundamental issues of pay-
load release. While for diagnostics, the imaging agent has to be strongly bound to the targeting unit for a specific 
detection, when a drug delivery system is designed, the in vivo rate of drug release from the conjugate and the 
tissue distribution pattern prior to that release have to be considered13. The ideal and smartest linker should be 
stable in blood circulation and extracellular sites, to avoid premature and unselective release of the drug, but it 
has to be easily cleavable when the tumor cells have been reached, affording in situ the native cytotoxic agent with 
restored efficacy. Among the variety of chemical structures applied as linkers, many are acid labile bonds (esters 
and hydrazones) that may be hydrolyzed in endosomal compartments, or specific peptide bonds recognized 
by lysosomal enzymes14. Following this approach, RGD-containing peptides have been successfully conjugated 
with diverse anticancer drugs, as doxorubicin, doxsaliform, monomethylauristatin E, cisplatin, camptothecin and 
paclitaxel15,16.
An important issue is also the increase in water solubility of the drug due to peptide or peptidomimetic conju-
gation that often leads to favorable availability of the drug17. Recently we have reported the synthesis and biolog-
ical evaluation of a small library of isoxazoline-based RGD mimetics where the pharmacophores were mimicked 
by malonic acid and aniline moieties18. Despite the known tox-risk associated to the presence of aniline, the mol-
ecules we already reported showed very good efficacy in binding the target receptors, probably as consequence 
of the basicity and length of this arginine-mimicking group. All the members of the library, differing only for the 
substituent in position 3 of the heterocycle, displayed excellent potency to modulate cell adhesion mediated by 
αvβ3 integrins (Fig. 1).
On the basis of this consideration, we selected the functionalization in position 3 as a useful anchorage of the 
heterocyclic scaffold for covalent ligation of diverse linkers, with the aim to not compromise the integrin binding 
capabilities. The purpose of this investigation is the synthesis of a variety of discretely sized ligand-linker systems 
to demonstrate the broad utility of the isoxazoline ligands for diverse and efficient bioconjugation strategies in 
drug and diagnostic tumor homing.
Results and discussion
Chemistry. To introduce a functionalizable chain in position 3 of the isoxazoline scaffold, we thought that a 
terminal alkyne could be a versatile moiety to be exploited in 1,3-dipolar Huisgen cycloaddition with different 
azide-linkers. To follow our previously reported synthetic protocol, 5-hexynal 1 had to be synthesized from the 
corresponding commercially available alcohol, via Swern oxidation with oxalyl chloride and TEA in DMSO (99% 
yield, Scheme 1). The Knövenagel reaction between 1 and t-butyl-acetoacetate afforded in 40% yield the alky-
lidene acetoacetate 2 as a 1/4 mixture of Z/E isomers (Scheme 1, path A). The unsatisfactory yield, never observed 
previously for simpler aldehydes, even using a microwave assisted protocol19, was attributed to alkyne side reac-
tions. For this reason, we protected the alkyne moiety with TMS group as reported by Cruciani and co-workers20. 
As a consequence, the Knövenagel reaction was performed using TiCl4/pyridine affording the alkyne-protected 
alkylidene acetoacetate 11 in 83% yield as 1/4 mixture of Z/E isomers as well and confirming the previous hypoth-
esis of alkyne side reactivity (Scheme 1, path B). Reaction conditions for the addition of bis-(N,O)-trimethylsi-
lylhydroxylamine to 2 and 11 were optimized on the basis of our previous experience21,22, in order to avoid the 
formation of oxime by-product as a result of the undesired 1,2-addition process23. According to these consider-
ations, the reaction was performed in DCM in the presence of a catalytic amount (5%) of ytterbium triflate as 
Lewis acid. It should be noticed that the TMS protecting group of the hydroxylamine was removed during the 
usual work up procedure, inducing the fast conversion of the intermediate adduct to trans 5-hydroxyisoxazo-
lidine-4-carboxylate 3 or 12, as a single trans epimer, via intramolecular hemiketalisation. Introduction of the 
malonic pharmacophore was performed at this stage by acylation at the nitrogen with methyl malonyl chloride, 
Figure 1. Potency of already reported isoxazoline-containing ligands measured in cell adhesion assay mediated 
by αvβ3 and α5β1 integrins. (ref. Cell adhesion assay in ChemMedChem 2011, 6, 2264–2272).
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in the presence of TEA. The isoxazolidines 4 or 13 were isolated in 51% and 50% respectively overall yield after 
two steps. Dehydration to the unsaturated racemic isoxazolines 5 or 14 was accomplished by mesylation of the 
hydroxyl group followed by base induced elimination. The removal of TMS protecting group on alkyne moiety 
of 14 by tetrabutylammonium fluoride afforded the product 5 in 53% yield. Selective removal of the t-butyl ester 
was then accomplished by treatment of 5 with an excess of trifluoroacetic acid in dichloromethane. The arginine 
mimetic chain was introduced by reaction of the acid 6 with 4-aminobenzylamine, following standard coupling 
conditions (HBTU/TEA in DCM) to give 7 in 76% yield. Hydrolysis of the methyl ester required a particular 
effort, since the undesired removal of the malonic side chain easily occurred, favored by the following spon-
taneous aromatization of the heterocycle as confirmed by LC-MS analysis. After several trials under different 
conditions, excellent results were obtained with a 7·10−3 M solution of LiOH·H2O in a 2:1 mixture of THF/water, 
following the reaction evolution by TLC, and stopping it at the disappearance of the starting ester. The acid 8 was 
obtained in quantitative yield.
In the design of the ligand-linker library, molecules terminating with an amine were prepared in order to 
obtain carriers for molecules with carboxylates or thiocarboxylates as active functionalization, as for instance 
the cytotoxic agent fumagillin or the fluorescein isothiocyanate diagnostic derivatives. To this purpose 
N-Boc-2-azido-ethylamine 15a and N-Boc-3-azido-propylamine 15b were prepared from the corresponding 
2-bromo-ethylamine and 3-bromo-propylamine by protection of the amino moiety followed by substitution of 
the bromide with NaN3. The two azides were then reacted with methyl ester 7 in the presence of 10% copper (0) 
powder and TEA·HCl salt at room temperature in a 1:1 mixture of t-BuOH and water24. The click reaction led 
to the exclusive formation of the desired 1,4-disubstituted [1,2,3]-triazoles 16a and 16b25 in 57% and 67% yield 
respectively. Removal of the methyl ester under the above reported conditions afforded compounds 17a (80%) 
Scheme 1. Synthetic pathways for the synthesis of methyl ester 7 and the corresponding acid 8, using the route 
(A) or (B) to evaluate the effects of alkyne-side chain on the yield of some critical steps of reaction.
4Scientific RepoRtS |         (2020) 10:7410  | https://doi.org/10.1038/s41598-020-64396-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
and 17b (87%) (Scheme 2, pathway A). Initially, the N-Boc protection at the linker amine moiety was retained in 
order to avoid the possible interference of a second amine group in the ligand-receptor binding. Moreover, it may 
mimic a carbamate linked payload.
For the preparation of molecules terminating with a carboxylate, able to conjugate drugs or diagnostics pos-
sessing functionalizable amines or hydroxyl groups, as for instance paclitaxel, compound 7 was submitted to 
Huisgen reaction in the presence of t-butyl 2-azido-acetate 18a and t-butyl 3-azido-propionate 18b, easily pre-
pared from the corresponding bromides. The cycloaddition afforded compounds 19a and 19b in low yield (20% 
and 34% respectively).
Complete regiocontrol was observed also in this case, affording exclusively the 1,4-disubstituted triazoles. 
Selective removal of the methyl ester was accomplished as reported above to afford acids 20a and 20b (Scheme 2, 
pathway B). Even in this case, the t-butyl group was retained to avoid interferences in the binding and to mimic 
the ester connection with a payload. In order to verify if elongation of the linker could turn into a lower interfer-
ence in integrin-ligand binding, we planned to synthesize more complex systems. The assembly of these compos-
ite molecules could be faced through several protocols, differing for the order of formation of the strategic bonds. 
Therefore, the synthetic protocol was optimized for each specific substrate. To obtain compound 24, having the 
succinic moiety as a typical and stable spacer between the carrier and the payload26, 3-bromo-propylamine was 
coupled with mono t-butyl pentandioic acid and the bromide was substituted with NaN3, to afford compound 
22 in good yield (90%). Then, the click reaction with methyl ester 7 was performed under the usual conditions 
(75% yield). Removal of the methyl ester moiety, afforded the acid 24 in 40% yield (Scheme 2, pathway C). The 
synthesis of the simpler compound 26 was accomplished in one step by performing the Huisgen reaction on the 
acid 8 with ethyl 5-azido-pentanoate. Due to the nature of substrate 8, the conditions of the reaction were mod-
ified and Cu(OAc)2 was used in the presence of sodium ascorbate27. The click reaction afforded 26 in 20% yield, 
as consequence of the difficulties in the purification of the product from the copper salts (Scheme 3, pathway E).
Many examples in the literature report the use of PEG as linker for drug-ligand connection for its ability to 
increase the solubility and to decrease the immunogenicity of the products28. Moreover, PEG-drug conjugates 
often exhibit a favourable in vivo behaviour and are less prone to enzymatic digestion. These data prompted us to 
design further carriers, containing the PEG fragment. To this purpose, compound 7 was reacted with commer-
cially available N-Boc-1-amino-3,6-dioxa-8-octaneazide (Boc-NH-PEG(2)-N3) as reported in Scheme 2 (path-
way D). Compound 27, isolated in 79% yield was then transformed into the corresponding acid 28 under the 
usual hydrolytic conditions (Scheme 2).
Finally, the acid 8 was treated with the PEG-azide 29, easily prepared from the corresponding commercially 
available acid. As previously observed, the nature of the starting isoxazoline suggested the use of Cu(OAc)2 and 
sodium ascorbate as catalysts (Scheme 3, pathway F). Under these conditions compound 30 was isolated in 40% 
yield given the difficult purification step. Fluorescent labelled molecules are useful for localization of proteins, vis-
ualization of intracellular processes and study of interactions between ligand and receptors. In particular, imaging 
by fluorescence provides many advantages in terms of selectivity and sensitivity of the detection. For this purpose, 
compound 17b, showing good selectivity and potency toward α5β1 integrins, was subjected to further function-
alization with a diagnostic dye. To this purpose, its precursor (16b) was deprotected at the N-terminal position 
of the side chain by using TFA in DCM, and conjugated with FITC (fluorescein isothiocyanate) in presence of an 
Scheme 2. Synthesis of ligands 17a,b, 20a,b, 24 and 28 functionalized by Huisgen 1,3-dipolar cycloaddition 
with copper (0) powder, TEA·HCl in tBuOH/H2O, starting from intermediate 7.
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excess of TEA in DCM. The FITC-labelled intermediate was subjected without further purification to the basic 
hydrolysis of the methyl ester, following the procedure previously reported, to afford the final compound 31 with 
50% yield over three steps (Scheme 4).
Pharmacological studies. Cell adhesion assay. In our previous experience, isoxazoline-based integrin 
ligands showed a strong potency towards αvβ3 and α5β1 integrins, not affected by changing the alkyl group linked 
to position 318. In designing this novel small library of peptidomimetics, alkyl chains were substituted by poly-
functionalized linkers including the triazole ring and amide, carbamate or ester moieties, that may create further 
interactions with the binding pocket. The ability of the synthesized racemic ligands to inhibit the adhesion of 
K562 cells (human erythroleukemic cells, expressing α5β1 integrin) or SK-MEL-24 cells (human malignant mel-
anoma cells, expressing αvβ3 integrin) to immobilized fibronectin was evaluated29. These cell models are widely 
used to investigate potential antagonists/agonists of α5β1 or αvβ3 integrin-mediated cell adhesion30–35. In these 
experiments, the cells were seeded onto plates coated with fibronectin and allowed to adhere before quantita-
tion of the number of adherent cells, in presence of increasing concentrations of the compounds. As a negative 
control, under these conditions, no significant cell adhesion was observed for BSA-coated plates or nonspecific 
substrate-coated plates (i.e., collagen I for SK-MEL-24 expressing αvβ3 and poly-L-lysine for K562 expressing α5β1 
integrin, data not shown). The ability of the new compounds to inhibit the adhesion of SK-MEL-24 and K562 
cells to fibronectin was compared with that of the standard antagonist compounds Ac-Asp-Arg-Leu-Asp-Ser-OH 
(Ac-DRLDS) and H-Gly-Arg-Gly-Asp-Thr-Pro-OH (GRGDTP), known to be potent inhibitors of cell adhesion 
mediated by αvβ3 and α5β1 integrins respectively36, and standard agonist Ref E (entry 15, Table 1), a potent and 
selective α5β1 ligand37. The obtained results are summarized in Table 1. From the results, it may be observed that 
the potency towards integrin αvβ3 is generally maintained, while few compounds show high potency towards 
α5β1. Compounds terminating with a carbamate moiety (17a, 17b and 28) behave as antagonists to integrin 
receptors, displaying anyway different selectivity. In particular, 17a displayed similar potency towards both recep-
tors (entry 2), while the longer 17b is an excellent selective ligand for α5β1 (entry 3), displaying IC50 in the low 
nanomolar range. The opposite preference could be observed for compound 28 that showed a good potency for 
αvβ3 receptor (entry 8). On the other hand, compounds having a terminal ester group (20a, 20b, 24, 26) in the 
side chain, behaved generally as agonists, inducing an increase in cell adhesion. All the molecules having a linear 
chain linked to the triazole ring (20a, 20b, 26) displayed high affinity for αvβ3 integrin (entries 4, 5 and 7) in the 
sub-micromolar range. By introducing an amide moiety in the central part of an elongated linker, as in com-
pound 24, the opposite selectivity was observed, still maintaining an agonist effect (entry 6). The introduction of 
a short PEG fragment induced complete loss of the activity (compound 30, entry 9). To complete the study, we 
also performed cell adhesion assay with the alkyne intermediate 8, which showed a good potency and selectivity 
for αvβ3. These data seem to suggest a possible influence of the terminal moiety on the agonist/antagonist role. A 
structure-activity relationship rationalization is still elusive, because agonist/antagonist behaviour38 for integrin 
ligands is known to depend also on the concentration39,40. Anyway, the good to excellent potency of the members 
of this class of peptidomimetics confirms their possible use as shuttle for drugs or diagnostic selective delivery to 
cells overexpressing these two classes of integrins.
Analysis of α5β1 integrin-mediated ERK phosphorylation. To gain further information about the agonist/antago-
nist role of our peptidomimetic integrin ligands and to verify the effect on intracellular signalling, we investigated 
the effect of most active compounds 17b and 24 on fibronectin-induced phosphorylation of ERK1/2 in K562 cells, 
which express α5β1 integrin. The mechanism by which components of extracellular matrix generate intracellular 
signalling through integrins requires indeed an increased phosphorylation of cytoplasmatic second messengers. 
Phosphorylation of ERK1/2 plays a central role in fibronectin-mediated survival signalling through integrins: in 
fact, cell adhesion activates ERK1/2 by binding of α5β1 integrins at the cell surface to extracellular matrix proteins 
such as fibronectin. The experiment was performed by serum-starving K562 cells in RPMI-1640 containing 1% 
Scheme 3. Synthesis of ligands 26 and 30 functionalized by Huisgen 1,3-dipolar cycloaddition with Cu(OAc)2, 
Na-Ascorbate in H2O, starting from intermediate 8.
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FBS for 16 h; thereafter, they were preincubated with compound 17b, 24 (10−7–10−9 M) or the vehicle for 60 min-
utes and then plated for 60 minutes on fibronectin.
When K562 cells were exposed to fibronectin for 60 minutes a much stronger signal was observed for phos-
phorylated ERK1/2, in comparison to vehicle-treated cells (Fig. 2).
Preincubation with compound 17b (10−7–10−9 M) caused a significant concentration-dependent reduction 
in the amount of fibronectin-induced ERK1/2 phosphorylation levels in K562 cells (Fig. 2), thus confirming a 
significant effect of the ligand binding on intracellular signalling cascade. On the contrary, when K562 cells, not 
preincubated with fibronectin, were exposed to compound 24, a significant concentration dependent increase in 
ERK1/2-phosphorylation was recorded thus confirming its agonistic behaviour (Fig. 2).
Integrin internalization. Integrin trafficking is an important mechanism employed by cells to regulate integ-
rin–extracellular matrix interactions, and thus cellular signalling, during processes such as cell migration and 
invasion42. α5β1 integrin is internalized, trafficked to recycling endosomes and then recycled to the plasma mem-
brane43,44. Membrane trafficking pathways influence α5β1’s ability to promote invasion and metastasis45,46. In order 
to investigate the effects of peptidomimetics on integrin trafficking, α5β1 integrin internalization was observed by 
confocal microscopy on HEK293 cells transfected with α5-enhanced green fluorescent protein (EGFP) plasmid 
(Fig. 3), as these cells endogenously express β1 subunit47,48. HEK293 + α5-EGFP cells were treated with fibronec-
tin (10 µg/mL) alone or in combination with the antagonist 17b (1 µM) or with the agonist 24 (1 µM) alone. As 
Scheme 4. Synthesis of targeting delivery system 31 by conjugation of intermediate 16b with FITC.
Entry Compound αvβ3 IC50/EC50 (µM)a α5β1 IC50/EC50 (µM)a
1 8 0.83 ± 0.05 agonist >1000
2 17a 0.88 ± 0.07 antagonist 0.28 ± 0.03 antagonist
3 17b >1000 0.0027 ± 0.0004 antagonist
4 20b 0.068 ± 0.011 agonist >1000
5 20a 0.23 ± 0.08 agonist >1000
6 24 >1000 6.59 ± 0.16 agonist
7 26 0.61 ± 0.08 agonist >1000
8 28 8.84 ± 0.14 antagonist >1000
9 30 >1000 >1000
10 31 n.d. 0.13 ± 0.01 antagonist
11b Ref A 0.032 ± 0.003 antagonist 0.012 ± 0.004 antagonist
12b Ref B 0.0088 ± 0.0006 antagonist 0.000105 ± 0.0003 antagonist
13b Ref C 0.360 ± 0.070 antagonist 1.320 ± 0.080 antagonist
14b Ref D 0.020 ± 0.006 antagonist 1.030 ± 0.050 antagonist
15c Ref E >1000 0.0129 ± 0.0006 agonist
16d,e,f Ac-DRLDS 0.025 ± 0.003 antagonist >1000
17d,f GRGDTP 0.926 ± 0.006 antagonist 0.00062 ± 0.00009 antagonist
18 g c(RGDfV) 0.146 ± 0.043 antagonist n.d.
19 h Cilengitide c(RGDf(NMe)V) 0.00058 ± 0.00001 antagonist n.d.
Table 1. Effects of isoxazoline ligands on αvβ3 and α5β1 integrin-mediated cell adhesion to Fibronectin (FN). 
[a] Data are presented as EC50 for agonists and as IC50 for antagonists (µM). Values are the mean ± SD of three 
independent experiments carried out in quadruplicate. [b] Compounds reported in Fig. 1 and extracted from 
reference18. [c] Ref E = 2-(2-(4-Oxo-(o-tolylcarbamoyl)azetidin-2-yl)acetamido)acetic acid. Extracted from 
reference37. [d] Reference compounds. [e] See reference41. [f] See reference38. [g] See reference32 and Mas-
Moruno et al. Anticancer Agents Med Chem. 2010, 10(10), 753–768. [h] See reference Dechantsreiter et al. J. 
Med. Chem. 1999, 42, 3033–3040. n.d.= not determined.
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shown in Fig. 3, after 15 minutes of treatment with the endogenous agonist fibronectin, α5β1 integrin was mainly 
localized in the cytoplasm (Fig. 3, panels d-f), if compared with vehicle-treated cells in which the integrin is quite 
completely located on the plasma membrane (Fig. 3, panels a-c). Moreover, when HEK293 + α5-EGFP cells were 
pre-treated with the antagonist 17b before the addition of fibronectin, it prevented integrin internalization, that 
remained mainly located on the membrane (Fig. 3, panels g-i). On the contrary, compound 24, mimicking the 
agonist behaviour of fibronectin, induced α5β1 internalization (Fig. 3, panels l-n): in fact, the integrin was mostly 
localized in the cytoplasm.
Stability assays. The ligand 17b, which showed best results in the pharmacological evaluation, was subjected to 
stability assays at neutral (pH=7), basic (pH=10) and acidic (pH=3) conditions, as representative of the class 
of compounds. LC-MS injections were performed after 30 min from the preparation of the samples and then 
after each 1.5 hours, following the experiments for 14 h (Fig. 4). During the last synthetic step, the methyl ester 
deprotection, the amidic bond between the heterocycle and malonyl group showed high sensitivity to the basic 
environment and, as expected, the hydrolysed A was detected in traces as the unique degradation product. As a 
consequence of the spontaneous aromatization of A, also an increasing amount of B was observed after a short 
period. The aromatised form B was tested to evaluate its effect on the activity of selected integrins but, as conse-
quence of the absence of a crucial pharmacophore, it was not active. This behaviour doesn’t represent a big issue 
since strong basic conditions are quite unusual in physiological environment. In fact under stress conditions with 
a large excess of base, the decomposition of 17b to A occurred in few minutes. On the contrary, during the acidic 
treatment and under neutral conditions, 17b resulted quite stable and after several hours only a 5% loss of product 
was detected, in favour of the formation of A and B. Finally, the stability of 17b was also checked in bovine serum, 
confirming that no significant degradation occurs in this physiological medium.
Confocal microscopic observation of isooxazoline FITC-conjugated distribution. In order to visualize the local-
ization of isoxazolines inside the cells and to explore the possibility to use them as shuttles for selective deliv-
ery of therapeutic payloads and diagnostics, compound 31 was synthesized conjugating 17b with FITC, as 
described above. This FITC conjugated isoxazoline maintained the ability to reduce K562 cells adhesion in a 
concentration-dependent manner, similar to compound 17b, but with a lower potency (IC50: 0.13 ± 0.01 μM). To 
study intracellular localization of compound 31, HEK293 cells were transfected with a plasmid coding for α5 
integrin subunit (HEK293 + α5), as they do not express this subunit endogenously47,48 but they express β1. 
When HEK293 + α5 cells were treated with 31 (0.1–1 μM) we observed that the compound was localized in 
the cell cytoplasm, as it could be internalized (Fig. 5). In addition, the internalization of compound 31 was 
concentration-dependent: at a higher concentration (1 μM) it accumulated inside the cells in a greater extent. 
Figure 2. (a) Cropped blots related to the effect of compounds 17b and 24 on α5β1 integrin-mediated 
phosphorylation of ERK1/2 in K562 cells. Cells were serum-starved in RPMI-1640 containing 1% FBS for 16 h; 
then cells were preincubated with different concentrations of the antagonist 17b (10−7–10−9 M) or its vehicle 
for 1 h in suspension and then were allowed to adhere for 1 h on fibronectin (FN). Cells treated with the agonist 
24 (10−7–10−9 M) were not incubated with fibronectin. Thereafter cells were lysed and lysates were analysed 
in Western blot using an antibody directed against phosphorylated ERK1/2 (pERK1/2) or total ERK1/2 
(totERK1/2). Western blot showed that cells plated on FN had a much stronger signal for phosphorylated 
ERK1/2 than vehicle-treated cells. Compound 17b prevented FN-induced phosphorylation of ERK1/2 in a 
concentration-dependent manner, while agonist 24 significantly increased ERK1/2 phosphorylation. Full-
length blots are presented in Supplementary Figure S40. (b) Densitometric analysis of the bands (Mean ± SEM; 
n = 4); the amount of pERK1/2 is normalized to that of totERK1/2. *p < 0.05, **p < 0.001 vs. FN; #p < 0.05. 
##p < 0.01 vs. vehicle (Newman-Keuls test after ANOVA).
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Moreover, we observed that the internalization of compound 31 is α5 integrin-mediated because it was not able 
to enter inside HEK293 cells that do not express α5 integrin endogenously (Fig. 5a).
In order to establish the possibility for compound 31 to be internalized also in cancer cells, endogenously 
expressing α5β1, K562 cells, derived from chronic myelogenous leukemia, were exposed to compound 31 
(0.1–1 μM), as reported in Methods section. As shown in Fig. 5b, compound 31 was internalized in K562 cells in 
a concentration-dependent way.
In addition, to confirm that compound 31 is internalized through an active mechanism of endocytosis, K562 
cells were exposed for 2 h to monensin (2 µM), which blocks the trafficking of α5 integrin from the Golgi stack 
to the trans Golgi network49. Inhibition of integrin trafficking prevented compound 31 internalization in K562 
cells (Fig. 5b); these results demonstrate that compound 31 enters cells relying on internalization rather than on 
passive permeability.
Figure 3. Confocal imaging on HEK293 cells transfected with α5-enhanced green fluorescent protein (EGFP) 
plasmid and treated with compounds 17b or 24. Panels (a-c) Vehicle-treated cells: integrins are located on the 
plasma membrane. Panels (d-f) FN-treated cells with 1 h incubation at 4 °C: α5β1 integrin was mainly located 
in the cytoplasm. Panels (g-i) FN-treated cells pre-incubated with the antagonist 17b for 20 minutes at 4 °C: 
compound 17b prevents FN-induced α5β1 internalization, being located in the cytoplasm. Panels (l-n) Cells 
treated with the agonist 24: mimicking FN agonistic effect, compound 24 induced α5β1 integrin internalization. 
Scale bar: 10 µm. The images have been elaborated using NIS-Elements C Software.
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As compound 31 derived from the conjugation of FITC to compound 17b that was a specific α5β1 integrin 
ligand, to confirm that the selectivity was maintained, we treated HEK293 cells transfected with plasmids coding 
for αv and β3 subunits (HEK293 + αvβ3) with compound 31 (0.1–1 μM) (Fig. 5c). In cells not expressing α5β1 
integrin compound 31 was not able to be internalized. These results confirm from one hand the α5β1-dependent 
internalization mechanism of compound 31 and from the other hand displayed that the specificity towards α5β1 
of compound 17b was maintained although conjugation with FITC molecule.
Computational studies. To rationalize the pharmacological activity observed for the new 
isoxazoline-RGD-mimetics, compounds 17b, 20b and 24 were selected to investigate the effects of the side chain 
in position 3 of the isoxazoline core on the interaction with the target receptors. In the family of the selective 
α5β1 ligands, we chose the most active compound 17b which inhibits α5β1 integrin-mediated cell adhesion at 
low nM concentrations, and compound 24 acting as an agonist of α5β1 receptor at µM levels. On the other hand, 
compound 20b was chosen as selective agonist ligand of αvβ3 integrin. Automated docking calculations were 
carried out with the Glide software package (version 7.0) by using the crystal structure of the extracellular seg-
ment of integrin α5β1 in complex with a disulfide-bonded cyclic RGD peptide (PDB code 4WK4) and the crystal 
structure of the extracellular domain of integrin αvβ3 in complex with the cyclic pentapeptide Cilengitide (PDB 
code 1L5G), according to the procedures reported in the Experimental Section. As the docking approaches were 
successful in reproducing the crystallographic binding mode of the cyclic peptides at the interface of the α and 
β subunits by means of electrostatic and H-bond interactions, we applied the same docking protocols to both 
enantiomers of compounds 17b, 20b and 24 to generate computational models for the interaction of these ligands 
with α5β1 and αvβ3 integrins and evaluate their ability to properly fit the receptor site. In all the calculations, the 
experimentally observed binding modes of the cyclic peptides with α5β1 and αvβ3 integrins were used as reference 
models for the analysis of the docking results in terms of protein-ligand interactions. Docking results pointed 
out that the (R) and (S) enantiomers of the new functionalized isoxazolines show different behavior, with better 
performances exhibited by the (R)-isomer, especially in the α5β1 integrin. Based on the number of docking poses 
reproducing the key interactions of the X-ray complex, (R)-17b was the best α5β1 ligand confirming the phar-
macological results. In the best pose of (R)-17b (as well as in ten other poses) into the α5β1 binding pocket, the 
carboxylate group of the ligand is coordinated to the metal cation in the MIDAS region of the β1 subunit, while 
the aniline moiety forms H-bond interactions with the negatively charged side chain of Asp227 in the α5 subunit 
(Fig. 6, left). Further stabilizing interactions involve the formation of H-bonds between the ligand carboxylate 
group and the backbone amide hydrogen of Asn224 and Ser134 (and Tyr133 in some poses) in the β1 unit, and 
π-stacking interactions between the ligand aromatic group and the α5-Phe187 side chain. A H-bond between 
the Boc carbonyl moiety of ligand and the amino group of β1-Lys182 side chain is also observed. The long-chain 
substituent (bearing the triazole ring) at the position 3 of the isoxazoline is well accommodated at the interface 
between the α and β subunit; in particular, the triazole ring establishes stabilizing contacts with the side chains 
of residues α5-Trp157, β1-Tyr133, β1-Ser177 and β1-Lys182 (Fig. 6, left). On the contrary, docking results show 
that most poses of compound 17b (both R and S enantiomers) into αvβ3 lack the H-bond interaction between the 
ligand aniline moiety and the side chain of αv-Asp218, and display an unfavorable arrangement of the long-chain 
substituent at the position 3 of the isoxazoline at the α/β integrin interface. Due to residue differences between the 
binding sites, the long chain bearing the triazole ring of compound 17b can fit unhindered only into the pocket 
available at the α5β1 interface, thus confirming the pharmacological results in terms of selectivity. A comparison 
Figure 4. Stability of 17b in neutral, basic, acidic and physiological conditions and its possible degradation 
pathway. Conditions: 17b (0.1 mmol) in 300 µl of solvent (water or bovine serum). 5 eq of LiOH·H2O or HCl 
1 M were added.
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of α5β1 and αvβ3 integrins highlights that the mutations of α5-Phe187 into αv-Tyr178 and of α5-Asp227 into 
αv-Asp218 might allow the aniline moiety of the ligand to maintain the same H-bond and π-stacking interactions 
in the two binding sites. Other mutations at the α/β interface modify size and shape of the pocket accessible to 
the isoxazoline substituent, thus affecting the ligand binding mode (see Supplementary Figure S41). Molecular 
dynamics simulations allowing partial receptor flexibility showed that (R)-17b maintains stable interactions with 
α5β1, similar to those observed in the docking poses. In particular, the long-chain substituent is firmly placed at 
the α/β integrin interface, with the triazole and the Boc carbonyl moiety engaged in interactions with residues 
α5-Trp157, β1-Tyr133 and β1-Lys182. Instead, the docking poses of compound 24 reveal some difficulties in estab-
lishing the key interactions with the α5β1 pocket, mainly due to the lack of a simultaneous favorable fitting of the 
long-chain substituent at the α/β interface. Compared to 17b a reduced number of docking poses reproducing 
the X-ray interactions is achieved and MD simulations confirm high mobility of (R)-24 in the binding pocket. 
The binding determinants of 20b were finally investigated. The docking poses of (R)-20b into αvβ3 integrin are 
characterized by the interaction of the carboxylate group with the metal cation in the MIDAS region and the 
Asn215 and Tyr122 residues in the β3 subunit, and by the interaction of the aniline moiety with the side chains of 
αv-Asp218 or αv-Asp150, and of αv-Tyr178. Moreover, the Boc carbonyl moiety of the substituent at the position 
3 of the isoxazoline can create H-bonds with the backbone amide hydrogen of αv-Ala149 or the guanidinium 
group of β3-Arg216, while the triazole ring can form H-bond or cation-π interactions with the side chain of 
β3-Arg214 (Fig. 6, right). Molecular dynamics simulations allowing partial receptor flexibility showed that (R)-
20b maintains stable interactions with αvβ3, especially those involving the acid pharmacophoric group and the 
triazole ring. In short, according to these results, only the subtle fitting of suitable features of the isoxazoline 
substituent with appropriate receptor traits at the α/β integrin interface seems to allow the optimal interaction 
Figure 5. Confocal microscopy images of HEK293 or HEK293 + α5, HEK293 + αvβ3 and K562 cells treated 
with compound 31 (Cpd 31). Cells were exposed to compound 31 (0.1–1 μM) or its vehicle for 60 minutes 
at 4 °C and thereafter cells were moved to 37 °C for 15 minutes to promote integrin internalization and fixed 
as described in Methods. a) Compound 31, conjugated with FITC was able to enter the cells in α5 integrin-
dependent manner: it was internalized in HEK293 + α5 but not in HEK293 cells. Right Panels: HEK293 cells 
not expressing α5 integrin subunit. Left Panels: HEK293 + α5. b) Concentration-dependent internalization of 
compound 31 was observed also in K562 cancer cells, endogenously expressing α5β1 integrin. Treatment with 
monensin (an inhibitor of integrin trafficking, 2 µM for 2 h) significantly inhibited compound 31 internalization 
in K562 cells. c) Compound 31 was not able to enter in HEK293 + αvβ3 cells, not expressing α5β1. In the left 
column of each panel green (FITC) fluorescence was shown, whereas in right one green and blue (DAPI) 
signals were merged. Nuclei were counterstained with DAPI. Scale bar: 30 µm. d) Compound 31 internalization 
was evaluated according to green fluorescence intensity in the cells and is reported in the graph. (Mean ± 
SEM; n = 2). ***p < 0.001 vs vehicle treated cells (Newman-Keuls test after ANOVA). The images have been 
elaborated using NIS-Elements C Software.
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of both the pharmacophoric moieties and the functionalizable chain of the isoxazoline-RGD-mimetics with the 
integrin binding site.
Conclusions
The synthesis of a small library of ligands obtained by conjugation of polyfunctionalized linkers to isoxazoline 
ring via Huisgen-click reaction, allowed to verify the possibility to use these scaffolds as αvβ3 and α5β1 targeting 
motifs, with the aim to use them as “shuttles” for selective delivery of therapeutics and diagnostics to cancer cells. 
The different behavior of the members of the library seems to suggest a correlation between the terminal moiety 
of the linker chain and the cell adhesion inhibition or activation, even if a rationale in structure-activity relation-
ship is not predictable and needs further investigation. Compound 17b, that showed excellent potency towards 
α5β1 integrin in the nanomolar range as antagonist, was selected for further investigation to establish the effect 
on fibronectin induced ERK phosphorylation. It was able to prevent fibronectin-induced α5-integrin-mediated 
ERK1/2 intracellular signaling activation and α5-integrin internalization.
Moreover, compound 31, isoxazoline FITC-conjugated derived from compound 17b, confirmed the possi-
bility to exploit these integrin ligands as “shuttles” for the selective delivery of therapeutics and diagnostics as 
consequence of its internalization only inside integrin expressing cells.
Finally, stability in water solution at different values of pH and in bovine serum was verified in order to con-
firm the potential exploitation of these peptidomimetic molecules for pharmaceutical applications.
Methods
All chemicals were purchased from commercial suppliers and used without further purification. Anhydrous sol-
vents were purchased in sure seal bottles over molecular sieves and used without further drying. Flash chroma-
tography was performed on silica gel (230–400 mesh). NMR Spectra were recorded with Varian Mercury Plus 400 
or Unity Inova 600 MHz spectrometers. Chemical shifts were reported as δ values (ppm) relative to the solvent 
peak of CDCl3 set at δ = 7.27 ppm (1H-NMR) or δ = 77.0 ppm (13C-NMR), CD3OD set at δ = 3.31 ppm (1H-NMR) 
or δ = 49.0 ppm (13C-NMR), D2O set at δ = 4.79 ppm (1H-NMR), CD3CN set at δ = 1.93 ppm (1H-NMR) or 
δ = 117.7 ppm (13C-NMR), (CD3)2CO set at δ = 2.04 ppm (1H-NMR) or δ = 29.8 ppm (13C-NMR). Coupling con-
stants are given in Hertz. LC-MS analyses were performed on an HP1100 liquid chromatograph coupled with an 
electrospray ionization-mass spectrometer using a Phenomenex Gemini C18–3 µ -110 Å column, H2O/CH3CN 
as neutral solvent at 25 °C or H2O/CH3CN with 0.2% formic acid as acid solvents (positive scan 100–500 m/z, 
fragmentor 70 eV). Another set of experiments has been performed on an HP1100 liquid chromatograph coupled 
with an electrospray ionization-ion trap mass spectrometer MSD1100 using a Phenomenex Zorbax C18–3.5 µ -80 
Å column, H2O/CH3CN with 0.08% trifluoroacetic acid as acid solvents (positive scan 100–500 m/z, fragmentor 
70 eV). Compounds 9 and 10 were synthesized following a known procedure and analytical data are in agreement 
with the literature. Analyses indicated by the symbols of the elements or functions were within ±0.4% of the 
theoretical values.
Synthesis. General procedure for the Swern oxidation: (1) and (10). In a 2-neck round bottom flask, 
equipped to perform reaction under N2 atmosphere, a solution of dimethyl sulfoxide (2.36 ml, 33.3 mmol) in 
DCM (8.2 ml) was added at −78 °C to a solution of oxalyl chloride (1.47 ml, 17.4 mmol) in DCM (33.4 ml), and 
the mixture was stirred for 5 min. After this time, the alcohol (14.5 mmol) in DCM (16.4 ml) was added dropwise 
Figure 6. (A) Docking best pose of (R)-17b (green) into the crystal structure of the extracellular domain of 
α5β1 integrin (α5 orange, β1 blue). Only selected integrin residues involved in the interactions with the ligand 
are shown. The metal ion at MIDAS is displayed as a magenta CPK sphere. Non polar hydrogens are hidden 
for better visual representation. (B) Docking best pose of (R)-20b (purple) into the crystal structure of the 
extracellular domain of αvβ3 integrin (αv grey, β3 red). The metal ion at MIDAS is displayed as a cyan CPK 
sphere. The image has been generated using Maestro graphical interface [Maestro, version 10.5, Schrödinger, 
LLC, New York, NY, 2016].
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in 5 min and the solution was then stirred for 15 min. TEA dry (10.1 ml, 72.5 mmol) was added dropwise and the 
mixture was stirred further at room temperature for 10 min. The mixture was diluted with 60 ml of Et2O and 30 ml 
of water. The organic layer, after dilution with Et2O, was washed with NH4Cl sat. (20 ml x 3). It was then dried 
over Na2SO4 and evaporated under reduced pressure to give the product as a yellow oil and used without further 
purifications.
(1) Y > 99%. Anal. Calcd. C6H8O (96.96): C 74.97 H 8.39. 1H-NMR (400 MHz, Chloroform-d) δ 9.79 (t, 
J = 1.3 Hz, 1 H), 2.59 (dt, J = 1.3, 7.2 Hz, 2 H), 2.26 (dt, J = 2.6, 7.2 Hz, 2 H), 1.96 (t, J = 2.6 Hz, 1 H), 1.84 (m, 2 H); 
13C-NMR (400 MHz, Chloroform-d) δ 200.1, 82.2, 68.6, 45.2, 20.0, 16.7.
Tert-butyl-2-acetyloct-2-en-7-ynoate (2). In a one-neck round bottom flask, 1 (18.1 mmol), tert-butyl acetoac-
etate (2.96 ml, 18.1 mmol) and piperidine (269 µl, 2.7 mmol) were stirred at room temperature for 24 h. The mix-
ture was diluted with EtOAc and washed with water (10 ml x 3). The organic layer was dried over Na2SO4 and then 
evaporated. The crude was purified with flash chromatography (silica gel, 99/1 cyclohexane/EtOAc) to obtain the 
product as a 1/4 mixture of E/Z isomers.
(2) Y = 40%. Anal. Calcd. C14H20O3 (236.14): C 71.29 H 8.56. 1H-NMR (400 MHz, Chloroform-d) δ 6.77 (t, 
J = 8.0 Hz, 1 H, E isomer), 6.74 (t, J = 7.6 Hz, 1 H, Z isomer), 2.42 (dt, J = 7.6, 7.2 Hz, 2 H), 2.29 (s, 3 H), 2.23 (dt, 
J = 2.4, 6.8 Hz, 2 H), 1.96 (t, J = 2.4 Hz, 1 H), 1.72 (m, 2 H), 1.53 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 
194.8, 165.5, 145.1, 138.6, 83.2, 82.1, 69.2, 28.6, 28.0, 27.0, 26.8, 18.0; LC-MS: rt=9.1 min, m/z: 259 [M + 23], 275 
[M + 39], 495 [2 M + 23].
Tert-butyl 2-acetyl-8-(trimethylsilyl)oct-2-en-7-ynoate (11). A 1 M solution of TiCl4 in DCM (29 ml, 29 mmol) 
was added dropwise to THF (53 ml) at 0 °C and the mixture was stirred for few minutes. Then tert-butyl acetoac-
etate (2.4 ml, 14.5 mmol) in THF (6.3 ml) and 9 (14.5 mmol) in THF (6.3 ml) were added at 0 °C; the mixture was 
stirred for 75 min. A solution of pyridine (5.1 ml, 58 mmol) in THF (10.1 ml) was then added dropwise in 90 min 
and the mixture stirred overnight. The solution was diluted with Et2O (60 ml) and washed with water (20 ml x 
3) and brine (15 ml x 3). The organic layer was dried over Na2SO4 and then evaporated. The crude product was 
purified by flash chromatography (silica gel, 98/2 cyclohexane/EtOAc) to obtain the product as a 1/4 mixture of 
E/Z isomers.
(11) Y = 83%. Anal. Calcd. C17H28O3Si (308.18): C 65,95 H 9,15. 1H-NMR (400 MHz, Chloroform-d) δ 6.75 
(t, J = 8.0 Hz, 1 H, E isomer), 6.73 (t, J = 7.6 Hz, 1 H, Z isomer), 2.39 (dt, J = 7.6, 7.6 Hz, 2 H), 2.28 (s, 3 H), 2.24 (m, 
2 H), 1.68 (m, 2 H), 1.53 (s, 9 H), 0.12 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 201.0 (E), 194.8 (Z), 165.5 
(Z), 163.3 (E), 145.8 (E), 145.4 (Z), 138.4 (Z), 137.9 (E), 105.9 (Z + E), 85.2 (Z + E), 82.1 (Z), 81.7 (E), 28.7 (Z + E), 
28.0 (Z), 27.9 (E), 27.8 (E), 27.4 (E), 27.2 (Z), 26.8 (Z), 19.5 (Z), 19.3 (E), 0.0 (Z + E); LC-MS: rt=12.5 min, m/z: 
331 [M + 23], 347 [M + 39], 639 [2 M + 23].
General procedure for the synthesis of isoxazolidine ring (3) and (12). In a 2-necked round bottom flask, equipped 
to perform reaction under N2 atmosphere, Yb(OTf)3 (76 mg, 0.123 mmol) was added to a solution of 2 or 11 
(2.46 mmol) in DCM (45 ml), and the mixture stirred for 10 min at r.t. After this time, N,O-bistrimethylsilyl 
hydroxylamine (1.05 ml, 4.92 mmol) was added at 0 °C and the mixture stirred for 30 min. The solution was 
diluted with DCM and washed with water (10 ml x 3), giving the crude product as yellow oil used without further 
purifications.
General procedure for the synthesis of acylated isoxazolidine ring (4) and (13). In two-necked round bottom 
flask, equipped to perform reaction under N2 atmosphere, TEA (514 µl, 3.69 mmol) and methyl malonyl chloride 
(396 µl, 3.69 mmol) were added at 0 °C to a solution of 3 or 12 (2.46 mmol) in DCM (12 ml). The mixture was 
stirred at room temperature for 2,5 h. The mixture was washed with water (10 ml x 3). The crude product was 
purified with flash chromatography (silica gel, 80/20 cyclohexane/EtOAc). The product was isolated as a yellow 
oil.
(4) Y = 51% (over two steps). Anal. Calcd. C18H27NO7 (369.18): C 58.62 H 7.37 N 3.79. 1H-NMR (400 MHz, 
Chloroform-d) δ 4.65 (dt, J = 6.8, 7.4 Hz, 1 H), 3.72 (s, 3 H), 3.59 (d, J = 15.5 Hz, 1 H), 3.53 (d, J = 15.6 Hz, 1 H), 
2.86 (d, J = 7.4 Hz, 1 H), 2.28–2.19 (m, 2 H), 1.92 (t, J = 2.4 Hz, 1 H), 1.83–1.74 (m, 2 H), 1.63 (s, 3 H), 1.64–1.52 
(m, 2 H), 1.46 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 169.3, 168.4, 167.5, 105.3, 83.7, 82.6, 68.7, 61.6, 59.1, 
52.3, 40.7, 33.9, 27.8, 24.6, 22.8, 17.8. LC-MS: t = 8.3 min, m/z: 370 [M + 1], 392 [M + 23], 761 [2 M + 23].
(13) Y = 50% (over two steps). Anal. Calcd. C21H35NO7Si (441.22): C 57.11 H 7.97 N 3.17. 1H-NMR (400 MHz, 
Chloroform-d) δ 4.64 (dt, J = 6.8, 7.2 Hz, 1 H), 3.67 (s, 3 H), 3.50 (s, 2 H), 2.82 (d, J = 7.2 Hz, 1 H), 2.21 (dt, J = 6.8, 
6.0 Hz, 2 H), 1.72 (m, 2 H), 1.62 (s, 3 H), 1.59–1.47 (m, 2 H), 1.42 (s, 9 H), 0.07 (s, 9 H); 13C-NMR (400 MHz, 
Chloroform-d) δ 169.2, 168.5, 167.6, 106.7, 105.4, 84.8, 82.6, 61.7, 59.2, 52.4, 40.8, 34.0, 27.9, 24.8, 22.9, 19.4, 0.1. 
LC-MS: t = 11.3 min, m/z: 442 [M + 1], 464 [M + 23], 905 [2 M + 23].
Synthesis of isoxazoline (5) from (4) and isoxazoline (14) from (13). In a two-necked round bottom flask, 
equipped to perform reaction under N2 atmosphere, TEA (530 µl, 3.8 mmol) and methanesulfonyl chloride 
(294 µl, 3.8 mmol) were added to a solution of 4 or 13 (1.9 mmol) in DCM (8 ml) at 0 °C, and the mixture stirred 
at room temperature for 24 h. The mixture was diluted with DCM and washed with water (10 ml x 3). The organic 
layer was dried over Na2SO4 and then evaporated under reduced pressure. The crude product was purified by 
flash chromatography (silica gel, 80/20 cyclohexane/EtOAc) giving the product as a white solid.
(5) Y = 51%. Anal. Calcd. C18H25NO6 (351.17): C 61.40 H 7.17 N 3.99. 1H-NMR (400 MHz, Chloroform-d) 
δ 5.30 (m, 1 H), 3.72 (s, 3 H), 3.58 (d, J = 15.9 Hz, 1 H), 3.46 (d, J = 15.9 Hz, 1 H), 2.29–2.14 (m, 2 H), 2.20 (s, 
3 H), 1.99 (m, 1 H), 1.92 (t, J = 2.4 Hz, 1 H), 1.76 (m, 1 H), 1.64–1.53 (m, 2 H), 1.48 (s, 9 H); 13C-NMR (400 MHz, 
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Chloroform-d) δ 166.8, 162.0, 161.0, 105.8, 83.8, 80.9, 68.4, 62.8, 52.2, 40.4, 32.4, 28.0, 26.7, 23.6, 17.8, 11.1. 
LC-MS: LC-MS: rt=10.1 min, m/z: 352 [M + 1], 374 [M + 23], 725 [2 M + 23].
(14) Y = 87%. Anal. Calcd. C21H33NO6Si (423.21): C 59.61 H 7.86 N 3.30. 1H-NMR (400 MHz, Chloroform-d) 
δ 5.30 (m, 1 H), 3.72 (s, 3 H), 3.58 (d, J = 15.9 Hz, 1 H), 3.46 (d, J = 15.9 Hz, 1 H), 2.24 (dt, J = 3.2, 7.2 Hz, 2 H), 
2.20 (s, 3 H), 1.92 (m, 1 H), 1.71 (m, 1 H), 1.64–1.53 (m, 2 H), 1.48 (s, 9 H), 0.12 (s, 9 H); 13C-NMR (400 MHz, 
Chloroform-d) δ 167.0, 167.9, 162.2, 161.1, 106.9, 106.0, 84.6, 81.1, 63.1, 52.4, 40.6, 32.8, 28.2, 23.9, 19.5, 11.3, 0.1; 
LC-MS: rt= 13.2 min, m/z: 424 [M + 1], 446 [M + 23],462 [M + 39].
Synthesis of isoxazoline ring (5) from (14) by TMS protecting group removal. To a solution of 14 (440 mg, 
1.1 mmol) in THF (2.3 ml), tetrabutylammonium fluoride trihydrate (656 mg, 2.08 mmol) was added and the 
mixture stirred overnight at room temperature. After adding 5 ml of H2O, THF was removed and the solution 
diluted with 10 ml of DCM. The organic layer was washed with water (5 ml x 3), dried over Na2SO4 and evapo-
rated. The crude product was purified by flash chromatography (silica gel, 8/2 cyclohexane/EtOAc) to obtain the 
product as a yellow oil. Yield of 5: 53%.
Removal of tert-butyl ester: synthesis of acid (6). In one-necked round bottom flask, to a solution of 5 (378 mg, 
1.08 mmol) in DCM (36 ml) trifluoroacetic acid (1.24 ml, 16.15 mmol) was added and the mixture stirred for 24 h. 
The solution was evaporated to obtain the desired product as brown oil.
(6) Y > 99%. Anal. Calcd. C14H17NO6 (295.11): C 56.82 H 5.82 N 4.74. 1H-NMR (400 MHz, Chloroform-d) 
δ 5.36 (m, 1 H), 3.73 (s, 3 H), 3.63 (d, J = 15.9 Hz, 1 H), 3.50 (d, J = 16.0 Hz, 1 H), 2.27 (s, 3 H), 2.20 (m, 2 H), 2.03 
(m, 1 H), 1.93 (t, J = 2.6 Hz, 1 H), 1.78 (m, 1 H), 1.65–1.52 (m, 2 H); 13C-NMR (400 MHz, Chloroform-d) δ 168.3, 
167.9, 167.0, 164.4, 104.2, 83.7, 68.7, 62.9, 52.6, 40.4, 32.3, 23.6, 18.0, 11.8; LC-MS: rt= 5.0 min, m/z: 296 [M + 1], 
318 [M + 23], 334 [M + 39], 613 [2 M + 23].
Synthesis of isoxazoline- 4-amino benzylamide (7). In two-necked round bottom flask, equipped to perform reac-
tion under N2 atmosphere, TEA (226 µl, 1.62 mmol) and HBTU (614 mg, 1.62 mmol) were added to a solution of 
6 (1.08 mmol) in DCM (7 ml), and the mixture was stirred at room temperature for 5 min. 4-aminobenzylamine 
(245 µl, 2.16 mmol) was then added and the mixture stirred for further 4 h. The mixture was diluted with DCM 
and washed with water (10 ml x 3). The organic layer was dried over Na2SO4 and then evaporated under reduced 
pressure. The crude product was purified by flash chromatography (silica gel, 80/20 cyclohexane/EtOAc) giving 
the product as a yellow oil.
(7) Y = 76%. Anal. Calcd. C21H25N3O5 (399.18): C 63.39 H 6.32 N 10.49. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.06 (d, J = 8.0 Hz, 2 H), 6.63 (d, J = 8.0 Hz, 2 H), 5.62 (bs, 1 H), 5.27 (m, 1 H), 4.41 (dd, J = 5.6, 14.0 Hz, 1 H), 4.29 
(dd, J = 5.2, 14.0 Hz, 1 H), 3.70 (s, 3 H), 3.58 (d, J = 15.9 Hz, 1 H), 3.44 (d, J = 16.0 Hz, 1 H), 2.38 (m, 1 H), 2.21 (m, 
1 H), 2.02 (s, 3 H), 1.97 (m, 1 H), 1.65 (m, 1 H), 1.58–1.51 (m, 2 H); 13C-NMR (400 MHz, Chloroform-d) δ 168.5, 
166.9, 162.0, 159.0, 145.9, 129.1, 127.6, 115.1, 106.5, 83.7, 69.3, 61.6, 52.4, 43.1, 40.5, 38.5, 32.6, 23.0, 17.3, 11.3; 
LC-MS: rt= 1.4 min, m/z: 400 [M + 1], 422 [M + 23], 438 [M + 39], 821 [2 M + 23].
General procedure for the hydrolysis of malonyl methyl ester. Synthesis of (8), (17a), (17b), (20a), (20b), 
(24),(28). In a one-necked round bottom flask, LiOH.H2O (5.24 mg, 0,125 mmol) was added to a solution of 
ester (0.125 mmol) in a 2/1 mixture of THF/H2O (18.75 ml). The reaction was stopped after disappearance of 
the starting material, following the evolution by TLC. The solution was neutralized adding dropwise HCl 1 M 
solution and then water was evaporated. The product was purified by flash chromatography (C18 reverse phase 
silica gel, 8/2 water/CH3CN).
(8) Y = 99%. Anal. Calcd. C20H23N3O5 (385.16): C 62.08 H 6.00 N 10.89. 1H-NMR (400 MHz, Methanol-d4) 
δ 7.04 (d, J = 8.2 Hz, 2 H), 6.66 (d, J = 8.2 Hz, 2 H), 5.43 (m, 1 H), 4.84 (m, 2 H), 4.36 (d, J = 14.6 Hz, 1 H), 4.17 (d, 
J = 14.6 Hz, 1 H), 2.22–2.11 (m, 2 H), 2, 18 (s, 3 H), 1.87 (bs, 1 H), 1.86 (m, 1 H), 1.66 (m, 1 H), 1.57–1.48 (m, 2 H); 
13C-NMR (400 MHz, Methanol-d4) δ 172.4, 172.0, 163.6, 158.3, 146.4, 128.3, 128.1, 115.2, 106.6, 83.2, 68.5, 62.3, 
42.3, 39.9, 32.8, 23.5, 17.3, 10.0. LC-MS: rt= 1.6 min, m/z: 386 [M + 1], 400 [M + 23], 771 [2 M + 1].
(17a) Y = 80%. Anal. Calcd. C27H37N7O7 (571.28): C 56.85 H 6.51 N 17.13. 1H-NMR (400 MHz, Methanol-d4) 
δ 7.64 (s, 1 H), 7.61 (bs, 1 H), 7.01 (d, J = 8.3 Hz, 2 H), 6.90 (bs, 1 H), 6.65 (d, J = 8.3 Hz, 2 H), 5.45 (m, 1 H), 4.85 
(m, 2 H), 4.39–4.32 (m, 3 H), 4.18 (d, J = 14.4 Hz, 1 H), 3.45 (t, J = 5.6 Hz, 2 H), 2.67 (t, J = 8.0 Hz, 2 H), 2.17 (s, 
3 H), 1.87–1.53 (m 4 H), 1.37 (s, 9 H). 13C-NMR (400 MHz, Methanol-d4) δ 169.7, 163.4, 163.0, 161.9, 158.5, 
147.3, 144.9, 129.3, 129.0, 121.9, 115.4, 107.3, 79.8, 61.3, 49.8, 42.7, 40.5, 38.8, 32.4, 28.3, 24.4, 23.2, 11.3; LC-MS: 
rt= 1.6 min, m/z: 572 [M + 1].
(17b) Y = 87%. Anal. Calcd. C28H39N7O7 (585.29): C 57.32 H 6.73 N 16.71. 1H-NMR (400 MHz, Methanol-d4) 
δ 7.69 (s, 1 H), 7.00 (d, J = 8.0 Hz, 2 H), 6.64 (d, J = 8.0 Hz, 2 H), 5.45 (m, 1 H), 4.35–4.31 (m, 3 H), 4.17 (d, 
J = 14.6 Hz, 1 H), 3.46 (d, J = 14.8 Hz, 1 H), 3.21 (d, J = 14.8 Hz, 1 H), 3.01 (t, J = 6.0 Hz, 2 H), 2.67 (t, J = 7.2 Hz, 
2 H), 2.17 (s, 3 H), 2.01–1.98 (m, 2 H), 1.86–1.61 (m, 4 H), 1.40 (s, 9 H); 13C-NMR (400 MHz, Methanol-d4) δ 
171.9, 169.5, 163.6, 161.7, 158.3, 147.4, 146.4, 135.7, 128.2, 122.0, 115.1, 106.5, 78.7, 62.3, 48.2, 42.2, 37.1, 32.8, 
30.1, 29.2, 27.3, 24.3, 24.1, 10.0. LC-MS: rt= 1.6 min, m/z: 586 [M + 1], 608[M + 23].
(20a) Y = 75%. Anal. Calcd. C26H34N6O7 (542.25): C 57.54 H 6.33 N 15.51. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.76 (s, 1 H), 7.47 (bs, 1 H), 7.41 (d, J = 8.0 Hz, 2 H), 7.28 (d, J = 8.0 Hz, 2 H), 5.51 (m, 1 H), 5.20 (s, 2 H), 4.50 
(d, J = 15.2 Hz, 2 H), 4.39 (d, J = 15.2 Hz, 2 H), 2.76–2.69 (m, 2 H), 2.20 (s, 3 H), 1.85–1.60 (m, 4 H), 1.45 (s, 9 H); 
13C-NMR (400 MHz, Chloroform-d) δ 173.6, 171.2, 169.9, 169.2,167.2, 147.0, 146.8, 134.1, 128.2, 122.4, 115.3, 
106.6, 82.4, 61.0, 51.4, 43.2, 34.0, 33.3, 27.8, 24.6, 24.0,11.0; LC-MS (acid eluents): rt= 9.4 min, m/z: 543 [M + 1], 
565 [M + 23].
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(20b) Y = 75%. Anal. Calcd. C27H36N6O7 (556.26): C 58.47 H 6.51 N 15.14. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.82 (bs, 1 H), 7.80 (s, 1 H), 7.44 (d, J = 8.0 Hz, 2 H), 7.34 (d, J = 8.0 Hz, 2 H), 5.50 (m, 1 H), 4.61–4.56 (m, 3 H), 
4.46 (d, J = 12.4 Hz, 1 H), 2.90–2.85 (m, 2 H), 2.75–2.71 (m, 2 H), 2.20 (s, 3 H), 1.86–1.65 (m, 4 H), 1.38 (s, 9 H); 
13C-NMR (400 MHz, Chloroform-d) δ 173.6, 170.8, 170.2, 169.6, 167.5, 147.0, 146.2, 133.8, 128.6, 122.0, 115.1, 
106.4, 80.9, 60.7, 48.2, 43.4, 35.4, 33.9, 30.8, 27.6, 24.8, 24.2,11.5; LC-MS(acid eluents): rt= 10.0 min, m/z: 557 
[M + 1], 579 [M + 23].
(24) Y = 40%. Anal. Calcd. C31H43N7O8 (641.32): C 57.85 H 6.73 N 15.27. 1H-NMR (400 MHz, Methanol-d4) 
δ 7.80 (s, 1 H), 7.43 (d, J = 8.0 Hz, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 5.52 (m, 1 H), 4.51 (d, J = 15.0 Hz, 1 H), 4.22–
4.35 (m, 3 H), 3.18–3.13 (m, 2 H),2.78–2.68 (m, 2 H), 2.63–2.57 (m, 2 H), 2.48–2.44 (m, 2 H), 2.21 (s, 3 H), 2.08–
2.03 (m, 2 H), 1,98–1,94 (m, 1 H), 1.87–1.83 (m, 1 H), 1.76–1.59 (m, 4 H), 1.41 (s, 9 H); 13C-NMR (400 MHz, 
Methanol-d4) δ 172.5, 172.2, 172.0, 169.1, 165.6, 162.7, 147.0, 146.5, 135.2, 128.6, 122.1, 115.3, 106.2, 80.8, 62.0, 
48.4, 42.8, 37.0, 33.1, 31.2, 30.8, 29.4, 28.8, 28.0, 24.4, 24.0,11.0; LC-MS (acid eluents): rt= 9.4 min, m/z: 642 
[M + 1], 664 [M + 23].
(28) Y = 28: 40%. Anal. Calcd. C31H45N7O9 (659.33): C 56.36 H 6.91 N 14.90. 1H-NMR (400 MHz 
Methanol-d4) δ 7.73 (s, 1 H), 7.03 (d, J = 8.4 Hz, 2 H), 6.67 (d, J = 8.4 Hz, 2 H), 5.47 (m, 1 H), 4.82 (m, 2 H), 4.51 (t, 
J = 5.2 Hz, 2 H), 4.37 (d, J = 14.6 Hz, 1 H), 4.20 (d, J = 14.6 Hz, 1 H), 3.87 (t, J = 5.2 Hz, 2 H), 3.60–3.57 (m, 4 H), 
3.46 (t, J = 5.6 Hz, 2 H), 3.19 (t, J = 6.0 Hz, 2 H), 2.71 (t, J = 6.8 Hz, 2 H), 2.20 (s, 3 H), 1.85–1.58 (m, 4 H), 1.42 
(s, 9 H); 13C-NMR (400 MHz, Methanol-d4) δ 175.4, 172.4, 170.3, 168.2, 158.2, 156.9, 147.3, 146.4, 128.4, 128.2, 
122.5, 115.1, 107.1, 78.7, 70.0, 69.8, 69.6, 69.0, 49.8, 42.2, 42.1, 39.8, 33.3, 29.3, 27.3, 24.9, 10.3 LC-MS(acid elu-
ents): rt= 9.9 min, m/z: 660 [M + 1], 682 [M + 23].
General procedure for the synthesis of azides (15a), (15b). In two-necked round bottom flask, equipped to per-
form reaction under N2 atmosphere, to a solution of 2-bromo-ethylamine hydrobromide or 3-bromo-propylamine 
hydrobromide (2,44 mmol) in DCM (12.2 ml), Boc2O (510 µl, 2.22 mmol) and TEA (464 µl, 3.33 mmol) were 
added at 0 °C and the mixture stirred at room temperature overnight. The mixture was then washed with NH4Cl 
saturated solution, NaHCO3 saturated solution, brine and evaporated to afford the N-Boc-bromo amine inter-
mediate as a colourless oil that was used without further purifications. The intermediate was dissolved in DMF 
(3.4 ml) and NaN3 (174 mg, 2.68 mmol) was added in one portion. The mixture was stirred at 60 °C for 4 h and 
then diluted with EtOAc and washed with water (10 ml x 3). The organic layer was evaporated after anhydrifica-
tion over Na2SO4 to give the azides as yellow oils.
(15a) Y = 70%. Anal. Calcd. C7H14N4O2 (186.11): C 45.05 H 7.59 N 30.13. 1H-NMR (400 MHz, Chloroform-d) 
δ 4.79 (bs, 1 H), 3.40 (t, J = 5.7 Hz, 2 H), 3.28 (m, 2 H), 1.43 (s, 9 H). 13C-NMR (400 MHz, Chloroform-d) δ 155.8, 
79.9, 50.8, 39.8, 28.2; LC-MS: rt= 6.5 min, m/z: 209 [M + 23], 372 [2 M + 1], 395 [2 M + 23].
(15b) Y = 90%. Anal. Calcd. C8H16N4O2 (200.13): C 47.88 H 8.06 N 27.99. 1H-NMR (400 MHz, Chloroform-d) 
δ 4.63 (bs, 1 H), 3.33 (t, J = 8.0 Hz, 2 H), 3.18 (m, 2 H), 1.71–1.77 (m, 2 H), 1.41 (s, 9 H). 13C-NMR (400 MHz, 
Chloroform-d) δ 162.2, 78.4, 48.7, 36.1, 31.0, 28.0; LC-MS: rt= 7.4 min, m/z: 223 [M + 23], 423 [2 M + 23].
Tert-butyl 4-((3-bromopropyl)amino)-succinate (21). In two-necked round bottom flask, equipped to perform 
reaction under N2 atmosphere, to a solution of mono tert-butyl pentandioic acid (100 mg, 0.57 mmol) in DCM 
(4 ml), HBTU (324 mg, 0.86 mmol), TEA (120 µl, 0.86 mmol) and 3-bromo propylamine hydrobromide (130 mg, 
0.63 mmol) were added and the mixture stirred at room temperature for 4 h. The mixture was diluted with DCM, 
washed with water (5 ml x 3) and evaporated. The crude product was purified by flash chromatography (silica gel, 
9/1 cyclohexane/EtOAc).
(21) Y = 50%. Anal. Calcd. C11H20BrNO3 (293.06): C 44.99 H 6.84 N 4.74. 1H-NMR (400 MHz, Chloroform-d) 
δ 5.93 (bs, 1 H), 3.43–3.36 (m, 4 H), 2.62–2.52 (m, 2 H), 2.40 (t, J = 6.8 Hz, 2 H), 2.07 (m, 2 H), 1.44 (s, 9 H); 
13C-NMR (400 MHz, Chloroform-d) δ 172.3, 172.2, 80.8, 38.0, 32.2, 31.1, 30.8, 30.7, 27.9; LC-MS: rt= 6.6 min, 
m/z: 316 [M + 23], 609 [2 M + 23].
General procedure for the synthesis of (18a), (18b), (22) and (25). Bromo derivative (1 mmol) was dissolved in 
DMF (1.4 ml) and NaN3 (71 mg, 1.1 mmol) was added. The mixture was stirred at 60 °C for 4 h and then diluted 
with EtOAc and washed with water (5 ml x 3).
(18a) Y = 45%. Anal. Calcd. C6H11N3O2 (157.09): C 45.67 H 7.05 N 26.64. 1H-NMR (400 MHz, Chloroform-d) 
δ 3.72 (s, 2 H); 1.48 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 167.2, 82.6, 50.6, 27.7. LC-MS: rt= 8.2 min, 
m/z: 180 [M + 23].
(18b) Y = 45%. Anal. Calcd. C7H13N3O2 (171.10): C 48.95 H 7.63 N 24.51. 1H-NMR (400 MHz, Chloroform-d) 
δ 3.50 (t, J = 6.4 Hz, 2 H); 2.48 (t, J = 6.8 Hz, 2 H); 1.45 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 169.7, 80.7, 
46.6, 35.9, 27.6. LC-MS: rt= 8.8 min, m/z: 194 [M + 23].
(22) Y = 90%. Anal. Calcd. C11H20N4O3 (256.15): C 51.62 H 7.88 N 21.90. 1H-NMR (400 MHz, Chloroform-d) 
δ 6.00 (bs, 1 H), 3.36–3.30 (m, 4 H), 2.56 (t, J = 6.8 Hz, 2 H); 2.40 (t, J = 6.8 Hz, 2 H), 1.80–1.72 (m, 2 H), 1.43 
(s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 172.4, 172.0, 80.8, 49.2, 37.0, 31.2, 30.8, 28.8, 28.0; LC-MS: rt= 
6.0 min, m/z: 279 [M + 23], 535 [2 M + 23].
(25) Y = 85%. Anal. Calcd. C7H13N3O2 (171.10): C 49.03 H 7.66 N 24.56. 1H-NMR (400 MHz, Chloroform-d) 
δ 4.10 (q, J = 7.2 Hz, 2 H), 3.27 (t, J = 6.4 Hz, 2 H), 2.31 (t, J = 6.8 Hz, 2 H), 1.73–1.57 (m, 4 H), 1.23 (t, J = 7.2 Hz, 
3 H); 13C-NMR (400 MHz, Chloroform-d) δ 172.9, 60.2, 50.9, 33.5, 28.2, 22.0, 14.1; LC-MS: rt= 8.0 min, m/z: 172 
[M + 1], 194 [M + 23].
Ethyl 2-(2-(2-azidoethoxy)ethoxy)acetate (29). [2-(2-azidoethoxy)ethoxy]acetic acid cyclohexylamine salt 
(250 mg, 0.87 mmol) was dissolved in Et2O (850 µl) and BF3.Et2O (107 µl, 0.87 mmol) was added at 0 °C. The 
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mixture was refluxed for 3 h and then evaporated. The crude product was purified by flash chromatography (silica 
gel, 1/1 EtOAc/cyclohexane) affording the pure product as a colourless oil.
(29) Y = 40%. Anal. Calcd. C8H15N3O4 (217.11): C 44.36 H 6.96 N 19.38. 1H-NMR (400 MHz, Chloroform-d) 
δ 4.20 (q, J = 7.2 Hz, 2 H), 4.14 (s, 2 H); 3.75–3.72 (m, 2 H), 3.70–3.66 (m, 4 H), 3.38 (q, J = 5.2 Hz, 2 H), 1.27 (q, 
J = 7.2 Hz, 3 H); 13C-NMR (400 MHz, Chloroform-d) δ 170.2, 70.8, 70.7, 70.5, 68.6, 60.6, 50.5, 14.0. LC-MS: rt= 
5.4 min, m/z: 218 [M + 1], 240[M + 23].
General procedure for the Huisgen reaction between methyl ester (7) and azides: (16a), (16b), (19a), (19b), (23), 
(27). In one-necked round bottom flask, in a mixture of tBuOH:H2O = 1:1 (1 ml) TEA (0.15 mmol) and HCl 
1 M (0.15 mmol) were added and stirred for 2 min. 7 (0.15 mmol), Cu(0) (0.015 mmol) and azide (0.15 mmol) 
were added and the mixture stirred at room temperature following the reaction by TLC. The mixture was filtered 
through celite to remove the copper powder and evaporated. The crude was purified by flash chromatography 
(silica gel, 9/1 EtOAc/cyclohexane).
(16a) Y = 57%. Anal. Calcd. C28H39N7O7 (585.29): C 57.42 H 6.71 N 16.74. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.44 (bs, 1 H), 7.29 (s, 1 H), 7.13 (d, J = 8.2 Hz, 2 H), 6.66 (d, J = 8.2 Hz, 2 H), 5.45 (m, 1 H), 5.09 (bs, 1 H), 4.42–
4.35 (m, 4 H), 3.69 (s, 3 H), 3.56 (d, J = 16.0 Hz, 1 H), 3.51 (m, 2 H), 3.46 (d, J = 16.0 Hz, 1 H), 2.72–2.67 (m, 2 H), 
2.24 (s, 3 H), 1.85 (m, 1 H), 1.75 (m, 1 H), 1.61–1.55 (m, 2 H), 1.39 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) 
δ 168.9, 167.1, 162.2, 158.9, 155.9, 147.3, 144.9, 129.3, 129.0, 121.9, 115.4, 107.3, 79.8, 61.2, 52.4, 49.8, 42.7, 40.5, 
32.3, 29.6, 28.3, 24.4, 23.2, 11.3; LC-MS: rt= 5.6 min, m/z: 586 [M + 1], 608 [M + 23].
(16b) Y = 67%. Anal. Calcd. C29H41N7O7 (599.31): C 58.08 H 6.89 N 16.35. 1H-NMR (400 MHz, 
Chloroform-d) δ 7.50 (bs, 1 H)7.35 (s, 1 H), 7.12 (d, J = 7.9 Hz, 2 H), 6.72 (d, J = 7.9 Hz, 2 H), 5.52 (m, 1 H), 4.88 
(bs, 1 H), 4.42 (m, 2 H), 4.27 (t, J = 6.9 Hz, 2 H), 3.71 (s, 3 H), 3.58 (d, J = 16.0 Hz, 1 H), 3.48 (d, J = 15.9 Hz, 1 H), 
3.10–3.05 (m, 2 H), 2.68 (m, 2 H), 2.24 (s, 3 H), 1.99–1.95 (m, 2 H), 1.75–1.84 (m, 2 H), 1.63–1.53 (m, 2 H), 1.43 
(s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 168.9, 167.1, 162.2, 158.9, 156.1, 147.2, 145.1, 129.2, 128.9, 121.4, 
115.3, 107.3, 79.4, 61.2, 52.4, 47.4, 42.7, 40.5, 37.4, 32.3, 30.5, 28.4, 24.4, 23.0, 11.3; LC-MS: rt= 6.3 min, m/z: 600 
[M + 1], 622 [M + 23].
(19a) Y = 20%. Anal. Calcd. C27H36N6O7 (556.26): C 58.19 H 6.51 N 15.10. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.54 (s, 1 H), 7.02 (d, J = 8.4 Hz, 2 H), 6.92 (bs, 1 H), 6.58 (d, J = 8.4 Hz, 2 H), 5.39 (m, 1 H), 4.26 (d, J = 6.0 Hz, 
2 H), 3.67 (s, 3 H), 3.58 (d, J = 16.4 Hz, 1 H), 3.50 (d, J = 16.4 Hz, 1 H), 2.81–2.70 (m, 2 H), 2.17 (s, 3 H), 1.81–1.51 
(m, 6 H), 1.46 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) δ 173.9, 171.0, 169.1,167.3, 163.9, 147.1, 146.4, 134.0, 
128.6, 122.2, 115.1, 106.3, 82.2, 60.8, 52.1, 51.6, 43.8, 33.4, 31.5, 27.9, 24.8, 24.3,11.8; LC-MS: rt= 6.8 min, m/z: 
557 [M + 1], 1135 [2 M + 23].
(19b) Y = 34%. Anal. Calcd. C28H38N6O7 (570.28): C 58.92 H 6.72 N 14.73. 1H-NMR (400 MHz, 
Chloroform-d) δ 7.50 (s, 1 H), 7.02 (d, J = 8.4 Hz, 2 H), 7.29 (bs, 1 H), 6.65 (d, J = 8.4 Hz, 2 H), 5.47 (m, 1 H), 4.55 
(bs, 1 H), 4.38–4.34 (m, 3 H), 4.18 (d, J = 14.4 Hz, 1 H), 3.67 (s, 3 H), 3.58 (d, J = 16.0 Hz, 1 H), 3.47 (d, J = 16.0 Hz, 
1 H), 2.80 (t, J = 6.4 Hz, 2 H), 2.72 (m, 1 H), 2.39 (m, 1 H), 2.10 (s, 3 H), 1.78–1.54 (m, 4 H), 1.38 (s, 9 H); 13C-NMR 
(400 MHz, Chloroform-d) δ; 173.7, 170.9, 169.6, 167.6, 164.2, 147.3, 146.6, 133.7, 128.4, 122.0, 115.3, 106.1, 81.3, 
60.6, 52.3, 48.8, 43.6, 35.4, 31.9, 30.4, 27.9, 24.6, 24.2,11.6. LC-MS: rt= 6.7 min, m/z: 571 [M + 1], 593 [M + 23].
(23) Y = 75%. Anal. Calcd. C32H45N7O8 (655.33): C 58.52 H 6.92 N 14.97. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.67 (s, 1 H), 7.07 (m, 1 H), 7.00 (d, J = 8.4 Hz, 2 H), 6.58 (d, J = 8.4 Hz, 2 H), 5.39 (m, 1 H), 4.50 (m, 2 H), 4.26 
(d, J = 5.6 Hz, 2 H), 3.67 (s, 3 H), 3.29 (m, 2 H), 3.16 (m, 2 H), 2.70–2.66 (m, 2 H), 2.53–2.48 (m, 2 H), 2.41–2.38 
(m, 2 H), 2.17 (s, 3 H), 2.07–2.00 (m, 2 H), 1.83–1.57 (m, 4 H), 1.41 (s, 9 H); 13C-NMR (400 MHz, Chloroform-d) 
δ 172.0, 168.5, 166.8, 161.9, 158.5, 146.9, 145.0, 128.7, 128.5, 121.4, 114.8, 107.0, 80.4, 61.0, 60.0, 52.1, 47.1, 42.3, 
40.2, 36.1, 32.0, 30.7, 30.3, 29.6, 27.7, 24.1, 13.8, 10.9; LC-MS: rt= 6.0 min, m/z: 656 [M + 1], 678 [M + 23].
(27) Y = 79%. Anal. Calcd. C32H47N7O9 (673.34): C 56.83 H 7.00 N 14.56. 1H-NMR (400 MHz, Chloroform-d) 
δ 7.53 (bs, 1 H), 7.45 (s, 1 H), 7.17 (d, J = 8.4 Hz, 2 H), 6.72 (d, J = 8.4 Hz, 2 H), 5.59 (m, 1 H), 4.95 (bs, 1 H), 4.47–
4.45 (m, 4 H), 3.82 (t, J = 5.2 Hz, 2 H), 3.71 (s, 3 H), 3.61–3.46 (m, 6 H), 3.28–3.26 (m, 2 H), 3.08 (m, 1 H), 2.72 (m, 
1 H), 2.27 (s, 3 H), 1.93–1.76 (m, 2 H), 1.63–1.54 (m, 2 H), 1.42 (s, 9 H), 1.27–1.22 (m, 2 H); 13C-NMR (400 MHz, 
Chloroform-d) δ 169.0, 167.0, 162.5, 162.2, 159.0, 155.9, 147.1, 145.2, 129.3, 129.1, 122.2, 115.2, 107.4, 70.5, 70.2, 
70.0, 69.5, 61.2, 52.4, 50.1, 42.7, 40.6, 36.4, 32.3, 29.6, 28.4, 24.6, 11.3; LC-MS: rt= 6.4 min, m/z: 674 [M + 1], 696 
[M + 23].
General procedure for the Huisgen reaction between acid (8) and azides: (26), (30). In one-necked round bot-
tom flask, in a mixture of tBuOH:H2O = 6:4 (4.5 ml) compound 8 (0.07 mmol), Cu(OAc)2 (2.5 mg, 0.014 mmol), 
Na-ascorbate (5.5 mg, 0.028 mmol) and azide (0.07 mmol) were added and the mixture was stirred at room tem-
perature following the reaction by TLC. The mixture was filtered through celite and evaporated. The product was 
purified by flash chromatography (C18 reverse phase silica gel, 8/2 water/CH3CN).
(26) Y = 20%. Anal. Calcd. C27H36N6O7 (556.26): C 58.08 H 6.52 N 15.13. 1H-NMR (400 MHz, Methanol-d4) 
δ 7.43 (s, 1 H), 7.24 (bs, 1 H), 7.04 (d, J = 8.0 Hz, 2 H), 6.64 (d, J = 8.0 Hz, 2 H), 5.46 (m, 1 H), 4.85 (m, 2 H), 4.35–
4.31 (m, 3 H), 4.18 (d, J = 15.0 Hz, 1 H), 4.08 (q, J = 7.6 Hz, 2 H), 3.19–3.14 (m, 2 H), 2.72–2.64 (m, 2 H), 2.32–2.30 
(m, 2 H), 2.20–2.15 (m, 2 H), 2.13 (s, 3 H), 2.01–1.98 (m, 2 H), 1.87–1.78 (m, 2 H), 1.71–1.52 (m, 2 H), 1.28 (t, 
J = 7.6 Hz, 3 H); 13C-NMR (400 MHz, Methanol-d4) δ 173.5, 172.9, 171.8, 169.4, 164.2, 147.2, 146.6, 133.9, 128.3, 
122.2, 115.4, 106.1, 61.4, 60.2, 49.2, 43.9, 36.4, 33.5, 30.5, 28.2, 24.5, 24.2, 22.0, 14.1, 10.2; LC-MS (acid eluents): 
rt= 9.0 min, m/z: 557 [M + 1], 579 [M + 23].
(30) Y = 40%. Anal. Calcd. C28H38N6O9 (602.27): C 55.98 H 6.34 N 13.94. 1H-NMR (400 MHz Methanol-d4) 
δ 7.82 (bs, 1 H), 7.27 (s, 1 H), 7.07 (d, J = 8.4 Hz, 2 H), 6.62 (d, J = 8.4 Hz, 2 H), 5.48 (m, 1 H), 4.86 (m, 2 H), 
4.56–4.47 (m, 3 H), 4.40 (m, 1 H), 4.18 (q, J = 7.2 Hz, 2 H), 4.11–4.05 (m, 2 H), 3.88–3.85 (m, 2 H), 3.75–3.56 (m, 
4 H), 2.70 (m, 1 H), 2.34 (m, 1 H), 2.20 (s, 3 H), 1.87–1.53 (m, 4 H), 1.26 (t, J = 7.2 Hz, 2 H)); 13C-NMR (400 MHz, 
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Methanol-d4) δ 175.5, 172.6, 170.5, 170.0,168.5, 147.1, 146.4, 128.6, 128.1, 122.4, 115.3, 107.2, 71.8, 70.8, 70.3, 
68.6, 61.6, 60.5, 49.8, 42.3, 39.7, 33.2, 29.3, 24.8, 11.3, 14.0. LC-MS: rt= 1.6 min, m/z: 603 [M + 1].
Synthesis of FITC-conjugated ligand (31). In one-necked round bottom flask, to a solution of 16b (12 mg, 
0.02 mmol) in DCM (100 µl) trifluoroacetic acid (21 µl, 0.3 mmol) was added and the mixture stirred for 2 h. The 
solution was evaporated to obtain the desired intermediate as an orange oil. It was dissolved in DCM (300 µl) and 
TEA (11 µl, 0.08 mmol) was added dropwise. After 10 min, FITC (7 mg, 0.02 mmol) was added and the mixture 
stirred overnight at room temperature. The solvent was removed under vacuum and the crude used without 
further purifications. It was dissolved in a 2/1 mixture of THF/H2O (2 ml) and LiOH.H2O (0.4 mg, 0,02 mmol) 
was added to a solution of ester. The reaction was stopped after disappearance of the starting material, following 
the evolution by HPLC-MS. The solution was neutralized adding dropwise HCl 1 M solution and then water was 
evaporated. The crude was purified by preparative HPLC, affording 10 mg of the desired product. LC-MS: rt= 
27.4 min, m/z: 875 [M + 1], 897 [M + 23].
Pharmacology. Cell Culture. SK-MEL-24 (American Tissue Culture Collection, ATCC, Rockville, MD) 
were routinely grown in minimum essential medium (MEM, Cambrex, Walkersville, MD) supplemented with 
10% fetal bovine serum (FBS), nonessential amino acids, and sodium pyruvate. K-562 (ATCC, Rockville, MD) 
were maintained as a stationary suspension culture in RPMI-1640 and L-glutamine with 10% FBS (Invitrogen 
(Carlsbad, CA). Cells were kept at 37 °C in a 5% CO2 humidified atmosphere. Forty hours before experiments, 
K-562 were treated with 25 ng/mL PMA (Sigma-Aldrich SRL, Milan, Italy) to induce differentiation and to 
increase expression of cell surface antigens50.
Cell adhesion assays. Plates (96 wells) (Corning Costar, Celbio, Milan,Italy) were coated by passive adsorption 
with fibronectin (10 µg/mL) or poly-L-lysine (0.002%) (Sigma-Aldrich SRL) overnight at 4 °C. Cells were counted 
with a haemocytometer and pre-incubated with different concentrations of each compound or with the vehicle 
(methanol) for 30 min at room temperature to reach a ligand-receptor equilibrium. Stock solutions (10–2 M) of 
the assayed compounds were prepared in phosphate-buffered saline (PBS). At the end of the incubation time, the 
cells were plated (50000 cells/well) and incubated at room temperature for 1 h. Then, all the wells were washed 
with PBS to remove nonadherent cells, and 50 µL of hexosaminidase [4-nitrophenylN-acetyl-β-D-glucosaminide 
dissolved at a concentration of 7.5 mM in 0.09 M citrate buffer solution (pH 5) and mixed with an equal volume of 
0.5% Triton X-100 in water] was added. This product is a chromogenic substrate for β-N-acetylglucosaminidase 
that is transformed in 4-nitrophenol whose absorbance can be measured at 405 nm. As previously described51, 
there is a linear correlation between absorbance and enzymatic activity. Therefore, it is possible to identify the 
number of adherent cells among treated wells, interpolating the absorbance values of unknowns in a calibration 
curve. The reaction was blocked by addition of 100 µL of a stopping solution [50 µM glycine and 5 µM EDTA 
(pH 10.4)], and the plates were read in an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). 
Experiments were carried out in quadruplicate and repeated at least three times. Data analysis and IC50/EC50 
values were calculated using Graph-Pad Prism 5.0 (GraphPad Software, San Diego, CA).
Western blotting analysis. K562 cells were incubated in RPMI-1640 with 1% FBS for 16 h. Plates were coated 
with 10 µg/ml of fibronectin and blocked with 1% BSA (Sigma-Aldrich SRL). Subsequently, 4 × 106 cells were 
pre-incubated with different concentrations of compounds for 30 minutes. Cells were allowed to adhere for 1 hour 
on fibronectin in RPMI-1640 with 1% FBS. Cells treated with agonists were not incubated with fibronectin. Then, 
the cells were lysed in M-PER Mammalian Protein Extraction Reagent; (M-PER Pierce, Rockford, IL, USA) sup-
plemented with phosphatase inhibitor (Sigma-Aldrich SRL) for 10 min at 4 °C by gently shaking. Cell debris were 
removed by centrifugation (14,000 × g for 15 minutes at 4 °C) and protein concentrations were estimated by 
BCA assay (Pierce, Rockford, IL, USA). Protein extracts (100 µg) were denatured at 95 °C for 3 min before being 
loaded and separated in 12% SDS–PAGE gels. The membranes were blocked in 1% BSA and incubated for 2 hours 
with anti-phospho-ERK 1/2 (extracellular signal-regulated kinase 1/2) (1:2500) or anti-total ERK 1/2 antibodies 
(1:5000) (Promega, Madison, WI, USA) and, thereafter with anti-rabbit peroxidase-conjugated secondary anti-
body. Digital images were acquired and analyzed following previously reported methods52.
Confocal laser scanning microscopy. HEK293 cells (not expressing α5 but endogenously expressing β1 integrin47,48 
were plated in 6 well plates and at 50–60% confluence were transiently transfected with α5-EGFP plasmid using 
Lipofectamine2000 transfection reagent (LifeTechnologies). After 48 h from transfection, HEK293 + α5-EGFP 
cells were assessed to verify integrins expression by flow cytometry (data not shown). α5-EGFP integrin plasmid 
was a kind gift from Michael Davidson (Addgene plasmid #56423). HEK293 + α5-EGFP cells were treated at 
4 °C with fibronectin (10 µg/ml) or the agonist 24 (1 µM) in MEM for 1 hour. Cells exposed to the antagonist 17b 
(1 µM), before the addition of fibronectin, were pre-incubated with the compound for 20 minutes at 4 °C. After 
1 h incubation with fibronectin or compound 24, cells were moved to 37 °C for 15 minutes. Then, the cells were 
washed twice with PBS and fixed with paraformaldehyde (3% in PBS, pH 7.4, 10 min). Thereafter, the cover slips 
were washed twice with 0.1 M glycine in PBS and twice with 1% BSA (bovine serum albumin) in PBS.
In another set of experiments, to study the localization of FITC-conjugated integrin ligand 31, K562 cancer 
cells or HEK293 cells transfected or not with α5 subunit coding plasmid (pCB7 alpha5) or with αv53 and β3 sub-
unit coding plasmids were treated with compound 31 (0.1–1 μM) for 60 minutes, moved to 37 °C for 15 minutes 
and then fixed as previously described. Monensin (2 µM, 2 h) was employed as an inhibitor of integrin trafficking, 
and was added 1 h before compound 31 addition to K562 cells. As K562 were grown in suspension and they could 
not be grown attached to glass coverslip, for confocal microscopy experiments cells were treated and fixed as 
described above and then centrifuged using cytospin technique (1200 rpm 5 min; 1 ml/sample of 0.5 mil cells/ml 
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solution). Nuclei were counterstained with 4’,6-diamidino-2-phenylindole dilactate (DAPI, Sigma). pCB7 alpha5 
was a gift from Filippo Giancotti (Addgene plasmid #1604154). αv integrin plasmid was a kind gift from Michael 
Davidson (Addgene plasmid no.57345), while β3 subunit coding plasmid was a kind gift of Prof. S.J.Shattil.
Specimens were embedded in Mowiol and analyzed using a Nikon C1s confocal laser-scanning micro-
scope, equipped with a Nikon PlanApo 60×, 1.4-NA oil immersion lens. The images have elaborated using 
NIS-Elements C Software.
For internalization analysis of ligand 31, the mean fluorescence intensity was related to the background; the 
relative fluorescence intensity is reported in the graph in Fig. 5.
Computational studies. All calculations were performed using the Schrödinger Suite through the Maestro 
graphical interface [Maestro, version 10.5, Schrödinger, LLC, New York, NY, 2016].
Ligand preparation. Ionized carboxylate and neutral aniline are suggested by the Epik module [Epik version 
3.5, Schrödinger, LLC, New York, NY, 2016] as the relevant protonation states at pH = 7 for the acid and basic 
pharmacophoric groups of isoxazoline derivatives according to predicted pKa values of 3.3 (carboxylic acid) 
and 4.6 (phenyl anilinium derivative). These protonation states were considered for computational studies of 
the isoxazoline-containing compounds. Ionized carboxylate and protonated guanidinium groups have been 
employed for the cyclic RGD integrin ligands.
Protein preparation. The crystal structure of the extracellular domain of the integrin α5β1 in complex with the 
disulfide-bonded cyclic peptide ACRGDGWC (PDB code 4WK4) and the crystal structure of the extracellular 
domain of the integrin αvβ3 in complex with the cyclic pentapeptide RGDf(NMe)V Cilengitide (PDB code 1L5G) 
were used for docking studies. The α5β1 integrin structure was set up for docking as previously reported (residues 
40–351 for chain α5 and 121–358 for chain β1, Mg2+ ion at MIDAS)55. The αvβ3 integrin structure was truncated to 
residue sequences 1–438 for chain αv and 107–354 for chain β3, and all the bivalent cations were modeled as Mn2+ 
ions. Then, the Protein Preparation Wizard using the OPLS2005 force field was run to get the final structures.
Molecular docking. Docking calculations were performed using Glide version 7.0 [Glide version 7.0, 
Schrödinger, LLC, New York, NY, 2016] in the SP (Standard Precision) mode. Receptor grids were generated on 
the extracellular fragments of α5β1 and αvβ3 integrin prepared as described in Protein Preparation. The settings of 
the docking step were defined as previously reported32,52. The GlideScore function was used to select 20 poses for 
each ligand after a post-minimization of the ligand structure within the binding site. The flexible-ligand docking 
method was selected and the SP mode was used with the option for amide bonds set to ‘Penalize non planar con-
formation’. No Epik state penalty was added to the docking score.
Each docking protocol was initially tested for its ability to reproduce the X-ray binding mode of the cyclic 
RGD ligand in the receptor crystal structure. Glide was successful in reproducing the experimentally determined 
binding mode of the cyclic peptide ACRGDGWC in α5β1 integrin and of Cilegitide in αvβ3 integrin, as they cor-
respond to the best-scored poses in the two docking runs.
Molecular dynamics simulations. Short MD simulations were run for selected derivatives to investigate the 
reliability of docking poses while allowing partial receptor flexibility. MD simulations were performed starting 
from the docking best poses and using MacroModel version 11.1 [MacroModel version 11.1, Schrödinger, LLC, 
New York, NY, 2016]. The following protocol was employed: OPLS2005 force field, implicit GB/SA water model, 
temperature 300 K, 1.0 fs integration step, 10 ps equilibration time and 10 ns simulation time. Variable degrees of 
freedom were assigned to the different moieties of the ligand-receptor complex, constraining the position of the 
atoms that are farthest from the receptor binding site and removing the interactions which are likely to have a 
negligible influence on the results. The ligand-integrin complex employed in the docking calculations is divided 
into four substructures according to the following scheme: the ligand is allowed to freely move, residues within 
10 Å from the ligand are constrained at the crystal positions with a force constant K = 100 kJ mol−1 Å−2, residues 
within 5 Å from the second shell are constrained at the crystal positions with a force constant K = 200 kJ mol−1 
Å−2, residues within 10 Å from the third shell are frozen in their respective crystal positions. The remaining res-
idues are not considered in the calculation. Each structure has undergone a TNCG minimization step and, after 
the equilibration at 300 K, 2.000 structures from each simulation were saved for the analysis.
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